The Medical Letter on Drugs and Therapeutics
Valbenazine (Ingrezza) for Tardive Dyskinesia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved valbenazine (Ingrezza – Neurocrine Biosciences), a vesicular monoamine transporter 2 (VMAT2) inhibitor, for treatment of tardive dyskinesia in adults.1 It is the first drug to be approved in the US for this indication; two other VMAT2 inhibitors, tetrabenazine (Xenazine, and generics) and deutetrabenazine (Austedo), were approved earlier for treatment of chorea associated with Huntington's disease.

TARDIVE DYSKINESIA — Tardive dyskinesia is a neurological disorder characterized by stereotypical, repetitive, involuntary movements of the mouth, tongue, face, trunk, and extremities. It can occur with prolonged use of antidopaminergic drugs, especially first-generation antipsychotics and metoclopramide (Reglan, and others).

There is no standard treatment for tardive dyskinesia. If possible, the precipitating drug should ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Valbenazine (Ingrezza) for Tardive Dyskinesia
Article code: 1521b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian